Novo Nordisk partners with Anthropic to accelerate drug R&D with Claude Science

Novo Nordisk, maker of Ozempic, announced a partnership with Anthropic to bring Claude into its drug discovery and development pipeline through a program called Claude Science. It is widely seen as a landmark case of AI4Science landing in the pharmaceutical industry.

Confirmed

• The partnership lets Novo Nordisk scientists use Claude models to accelerate drug discovery and development.
• Per @HealthcareAIGuy, Claude will be applied to scientific reasoning, biology research, and agentic software engineering, embedded in the company's core R&D workflows.
• Per @Polymarket, the odds of the FDA approving Eli Lilly's Retatrutide this year stand at just 3% (about $586K in volume). Retatrutide is a triple-agonist peptide targeting obesity, fatty liver disease, and type 2 diabetes.

Why it matters

• @DrSingularity frames it as bio/acc: embedding frontier AI into every step of scientific research, scaled by autonomous agents.
• @AllThingsApx argues every life-science lab needs an AI strategy combining frontier models for reasoning, domain-specific models for biology, and proprietary models for lab data.
• @emmanuelvivier and @HealthcareAIGuy both see it as another major pharma deeply embedding AI into core R&D.

2026-09-16 ~ 2026-09-18 · 6 related posts

• Ozempic maker Novo Nordisk partners with Anthropic's Claude Science for drug development — Polymarket · 2026-09-16
• Novo Nordisk partners with Anthropic to speed drug development using Claude Science — Polymarket · 2026-09-16
• Novo Nordisk partners with Anthropic to bring AI into drug discovery — AllThingsApx · 2026-09-17
• [source] Novo Nordisk partners with Anthropic: Claude Science to speed up drug discovery — emmanuelvivier · 2026-09-17

2 near-duplicate retellings: Dr_Singularity · HealthcareAIGuy